A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors
Shinkoda, Y., Shirahata, A., Fukutake, K., Takamatsu, J., Shima, M., Hanabusa, H., Mugishima, H., Takedani, H., Kawasugi, K., Taki, M., Matsushita, T., Tawa, A., Nogami, K., Higasa, S., Kosaka, Y., FuLanguage:
english
Journal:
Haemophilia
DOI:
10.1111/hae.13050
Date:
August, 2016
File:
PDF, 165 KB
english, 2016